Feasibility of HIFU for Management of Placenta Accreta (HIFU-ACCRETA) (HIFU-ACCRETA)
Primary Purpose
Placenta Accreta
Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
High Intensity Focused Ultrasound
Sponsored by
About this trial
This is an interventional treatment trial for Placenta Accreta focused on measuring High Intensity Focused Ultrasound (HIFU), Placenta accreta, Feasibility, Safety
Eligibility Criteria
Inclusion Criteria:
- Pregnant woman aged 18 years or older, with a suspicion of placental accretion observed with usual imaging tests (ultrasound, MRI)
- Single pregnancy (singleton)
- For whom a caesarean section has been scheduled
- Wishing to try to preserve her uterus
- Affiliated to a social security scheme or similar
- Having signed informed consent for participation in the study
Exclusion Criteria:
- Major patient protected by law, under guardianship or curatorship
- Patient participating in other interventional research that may interfere with this research
- Placental tumor identified in antenatal
- Grade 3 placental calcification
- Presence of a catheter, stent or vascular prosthesis close to the uterus
Sites / Locations
- Hospices Civils de Lyon - Hôpital de la Croix Rousse
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Per-caesarean HIFU shots
Arm Description
Adjuvant treatment with High Intensity Focused Ultrasound (HIFU) performed the day of the scheduled childbirth, after confirmation of placenta accreta, and after fetal extraction by caesarian section.
Outcomes
Primary Outcome Measures
Success of HIFU per-caesarean shots
Number of patients for whom: the probe is positioned in contact with the uterine serosa; and, one or more lesions of at least 1 cm each are visible on intraoperative ultrasound; and, total intervention time is 60 minutes maximum; and, no lesion are visible on the uterus; and, constants are maintained during the intervention; and, no related complication occurred during the intervention.
Secondary Outcome Measures
Ultrasound characteristics of placental lesions produced over time
MRI characteristics of placental lesions produced over time
Characteristics of lesions produced by macroscopic and microscopic pathological examination of the placenta (only in case of hysterectomy)
Spontaneous uterine vacuity
evaluated by endovaginal ultrasound examination. This examination will be supplemented by a liquid contrast ultrasound in accordance with standard clinical practices to identify the possible presence of synechia
Spontaneous uterine vacuity delay
measured in daytime. This is an estimate. After surgery on the uterus (e.g. hysterectomy, hysteroscopy, aspiration-curetage endo-uterin) it is considered that spontaneous uterine emptiness is not obtained.
Occurrence of a complication (hemorrhage, infection or other)
Full Information
NCT ID
NCT04003428
First Posted
April 25, 2019
Last Updated
November 13, 2020
Sponsor
Hospices Civils de Lyon
1. Study Identification
Unique Protocol Identification Number
NCT04003428
Brief Title
Feasibility of HIFU for Management of Placenta Accreta (HIFU-ACCRETA)
Acronym
HIFU-ACCRETA
Official Title
Perioperative Evaluation of High Intensity Focalized Ultrasound for Adjuvant Management of Placenta Accreta: a Clinical Feasibility Study
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 2021 (Anticipated)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
January 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Placental accretion during pregnancy refers to an abnormally deep insertion of the placenta into the uterus, leading to the impossibility of removing the placenta without inducting uterine or surrounding organs lesions. The management of these patients is complex, with two options during caesarean section: hysterectomy or uterine conservative surgery in which the placenta is let in the uterine cavity. These are both at risk of complications, including severe hemorrhage.
High Intensity Focused Ultrasound (HIFU) principle is based on the focusing of ultrasonic waves in a focal zone causing a rapid rise in temperature in the targeted area. This focus results in the creation of a coagulation necrosis tissue lesion. This procedure is guided in real time by an integrated ultrasound imaging cell.
The investigators hypothesized that HIFU shots would accelerate the process of placental involution when the placenta is let in the uterine cavity, increasing the chances of uterine preservation and reducing the infectious and hemorrhagic risks in the short and medium term. The aim of this study is to confirm the feasibility and safety of the use of HIFU as a per-caesarean adjuvant treatment for management of placenta accrete let in the uterus for a conservative treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Placenta Accreta
Keywords
High Intensity Focused Ultrasound (HIFU), Placenta accreta, Feasibility, Safety
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
3 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Per-caesarean HIFU shots
Arm Type
Experimental
Arm Description
Adjuvant treatment with High Intensity Focused Ultrasound (HIFU) performed the day of the scheduled childbirth, after confirmation of placenta accreta, and after fetal extraction by caesarian section.
Intervention Type
Device
Intervention Name(s)
High Intensity Focused Ultrasound
Intervention Description
HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
Primary Outcome Measure Information:
Title
Success of HIFU per-caesarean shots
Description
Number of patients for whom: the probe is positioned in contact with the uterine serosa; and, one or more lesions of at least 1 cm each are visible on intraoperative ultrasound; and, total intervention time is 60 minutes maximum; and, no lesion are visible on the uterus; and, constants are maintained during the intervention; and, no related complication occurred during the intervention.
Time Frame
Up to 30 days after procedure
Secondary Outcome Measure Information:
Title
Ultrasound characteristics of placental lesions produced over time
Time Frame
Up to 6 months after procedure
Title
MRI characteristics of placental lesions produced over time
Time Frame
Up to 6 months after procedure
Title
Characteristics of lesions produced by macroscopic and microscopic pathological examination of the placenta (only in case of hysterectomy)
Time Frame
Up to 6 months after procedure
Title
Spontaneous uterine vacuity
Description
evaluated by endovaginal ultrasound examination. This examination will be supplemented by a liquid contrast ultrasound in accordance with standard clinical practices to identify the possible presence of synechia
Time Frame
Up to 6 months after procedure
Title
Spontaneous uterine vacuity delay
Description
measured in daytime. This is an estimate. After surgery on the uterus (e.g. hysterectomy, hysteroscopy, aspiration-curetage endo-uterin) it is considered that spontaneous uterine emptiness is not obtained.
Time Frame
Up to 6 months after procedure
Title
Occurrence of a complication (hemorrhage, infection or other)
Time Frame
Up to 6 months after procedure
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pregnant woman aged 18 years or older, with a suspicion of placental accretion observed with usual imaging tests (ultrasound, MRI)
Single pregnancy (singleton)
For whom a caesarean section has been scheduled
Wishing to try to preserve her uterus
Affiliated to a social security scheme or similar
Having signed informed consent for participation in the study
Exclusion Criteria:
Major patient protected by law, under guardianship or curatorship
Patient participating in other interventional research that may interfere with this research
Placental tumor identified in antenatal
Grade 3 placental calcification
Presence of a catheter, stent or vascular prosthesis close to the uterus
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cyril HUISSOUD
Phone
+33 4 72 07 29 09
Email
cyril.huissoud@chu-lyon.fr
Facility Information:
Facility Name
Hospices Civils de Lyon - Hôpital de la Croix Rousse
City
Lyon
ZIP/Postal Code
69004
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cyril HUISSOUD
Phone
+33 4 72 07 29 09
Email
cyril.huissoud@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Cyril HUISSOUD
12. IPD Sharing Statement
Learn more about this trial
Feasibility of HIFU for Management of Placenta Accreta (HIFU-ACCRETA)
We'll reach out to this number within 24 hrs